Navigation Links
MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
Date:8/5/2008

MONMOUTH JUNCTION, N.J., Aug. 5 /PRNewswire/ -- MicroDose Technologies Inc. (MicroDose) today announced that the first clinical milestone in its collaboration with Merck & Co., Inc., through a Merck affiliate, has been achieved, triggering the first payment under the global license agreement for MicroDose's dry powder inhaler (DPI) technology announced in March 2008. This milestone signals the initiation by Merck of a Phase I clinical study of an investigational compound using the MicroDose DPI technology.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070803/NYF045LOGO )

As previously announced, Merck will fund development and commercialization of products that employ MicroDose's DPI technology for the administration of Merck compounds. In addition to the upfront payment received upon commencement of the collaboration, MicroDose is eligible for additional milestone payments on this product and for the development of other products and royalties on revenues from all products developed under the license.

"MicroDose is proud to announce the start of the study by Merck which, in fact, represents the second human clinical study to be initiated under a U.S. Investigational New Drug application using our inhaler technology in the last 18 months" commented David Byron, Vice President of Research and Development, MicroDose. "Achieving this milestone with Merck so quickly is a strong indicator of the excellent working relationship that underpins this collaboration."

About the MicroDose DPI

The MicroDose DPI is among a number of key proprietary drug delivery platforms developed by MicroDose. By employing piezo electronics, the MicroDose DPI has the potential to deliver enhanced performance for efficient and reproducible delivery independent of patient coordination, inhalation rate and posture, features MicroDose hopes will be confirmed through clinical t
'/>"/>

SOURCE MicroDose Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
2. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
3. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
4. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
5. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
6. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
7. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
8. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
9. Senesco Technologies Initiates Preclinical Studies for Cancer Target
10. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
11. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2009)...ewswire/ -- FUJIFILM Medical Systems USA, Inc. is ...y flat panel DR cassette, at the 2009 Radiological...Ideal for any clinical environment, FDR D-EVO uses...s with Fujifilm,s trademark image quality and outs...for users to transition to DR without modification...
(Date:11/29/2009)...ewswire/ -- Stimulated by the ten years of Synapse... Systems USA announced today, at the Radiological ...e formation of its Medical Informatics Division ....up will integrate all functions associated with th...tform for future growth. ,, Several organizatio...
(Date:11/29/2009)...ewswire/ -- Researchers using functional magnetic ... have found that men and women respond differently...study presented today at the annual meeting of the..., "Men may direct more attention to sensory aspec...n terms of implications for required action, where...
Breaking Medicine Technology:FUJIFILM's DR Cassette Makes World Debut 2FUJIFILM Establishes Medical Informatics Organization 2FUJIFILM Establishes Medical Informatics Organization 3New Study Finds Men and Women May Respond Differently to Danger 2New Study Finds Men and Women May Respond Differently to Danger 3New Jersey Dietetic Association Names Ketchums Jaime Schwartz Young Dietitian of the Year 52263 1New Jersey Dietetic Association Names Ketchums Jaime Schwartz Young Dietitian of the Year 52263 2New Jersey Dietetic Association Names Ketchums Jaime Schwartz Young Dietitian of the Year 52263 3Tips from the journals of the American Society for Microbiology 52258 1Tips from the journals of the American Society for Microbiology 52258 2Tips from the journals of the American Society for Microbiology 52258 3Tips from the journals of the American Society for Microbiology 52258 4Life on Earth came from other planets 9299 1Life on Earth came from other planets 9299 2Life on Earth came from other planets 9299 3Life on Earth came from other planets 9299 4
...to Explore the Efficacy of Novel Proteasome Inhibi...ry Multiple Myeloma, SOUTH SAN FRANCISCO, Calif. ...Research Consortium (MMRC) and Proteolix, Inc. tod...n a multi-center Phase 2,clinical trial to study P...or, carfilzomib (PR-171), in patients with relapse...
...nn., Aug. 15 Kevin McHale is,one of five board me..., a,non-profit organization incorporated in Saint ...sperson. HMH was created to gift cochlear implants... never be able to obtain one.,Dr. William House, t...its,on the Board of Directors., While the burden ...
Other Medicine Technology:The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 2The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 3The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 4Kevin McHale Instrumental in Forming the 'Help Me Hear Foundation' 2
(Date:11/27/2009)... GSI Group Inc. (Pink She...n technology products and semiconductor systems, t...ny,s shareholders has been scheduled for Friday, A...ng will be announced in due course. As previously...ice from Stephen Bershad, a holder of greater than...
(Date:11/27/2009)...m Replikins Ltd. today issued its latest biochemic...ows that the lethality of the virus has dropped fr...urrent outbreak in the spring of 2009 to resting n...e H1N1 infectivity count, however, remains increas...mber 27, 2009 -- Biotech firm Replikins Ltd., whic...
(Date:11/27/2009)...Newswire-FirstCall/ -- The Gymboree Corporation (N...OO, will present at the NASDAQ OMX 23rd Investor P...n London, England, on Wednesday, December 2, 2009,...dcast of The Gymboree Corporation,s presentation o...m, click on "Our Company" at the bottom of the pag...
(Date:11/27/2009)...ce, Nov. 27 Team Garmin-Slipstream...icated to ethical sporting and developing the next...that it will become Team Garmin-Transitions with t...r of the team. Transitions Optical is the world,s ... the most advanced photochromic technology in the ...
(Date:11/27/2009)...ldings has announced that it has become a national...argest nonprofit organizations dedicated to arthri... Delray Beach, FL (Vocus) Novemb...O), a company specializing in the marketing and re... has announced today that is has become a national...
Breaking Medicine News(10 mins):Health News:GSI Group Calls Shareholders Meeting 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4
...ide web foundation for the newly launched "indepen... Univita Health, a new company aimed at promoting...ndent aging, announced the acquisition of ENURGI, ... a virtual marketplace for individuals to find pro...
...fers quick-reference materials and multimedia tool...owing a child,s diagnosis , , BRIDGEWATER, N.J., ...ailability of the diabetes KidCare Kit, a multimed...st 30 days following a diagnosis of type 1 diabete...
...s the best way of spotting trouble, experts say , ...r versions of the stool-based colon cancer tests -...ry widely in their ability to spot potential abnor...e undetectable traces of blood that could come fro...
...Feb. 3 SuperGen, Inc. (Nasdaq: SUPG ), a pharma...velopment of novel cancer therapies, today announc...f Executive Officer, is scheduled to present at th...r Conference is scheduled to begin at 11:30 a.m. E...
...d Living Made Easy and Delicious with New Yoplait ... Probiotic Cultures , , MINNEAPOLIS, Feb. 3 Prob...th the latest flavor craze in the launch of Yoplai...men are familiar with probiotics, a strong indicat...
...Feb. 3 Alsius Corporation (Nasdaq: ALUS ), the ...gement (IVTM(TM)) therapies for critically ill pat...ond aggressively to the patent lawsuit brought aga...ement patents ZOLL purchased from a defunct compet...
Other Medicine News:Health News:Univita Health Acquires Leading Web Services Company 2Health News:New Diabetes Resource Provides Tools and Support to Families of Newly-Diagnosed Children with Type 1 Diabetes 2Health News:New Diabetes Resource Provides Tools and Support to Families of Newly-Diagnosed Children with Type 1 Diabetes 3Health News:New Diabetes Resource Provides Tools and Support to Families of Newly-Diagnosed Children with Type 1 Diabetes 4Health News:Stool-Based Colon Cancer Tests Vary Widely in Accuracy 2Health News:Stool-Based Colon Cancer Tests Vary Widely in Accuracy 3Health News:SuperGen to Present at BIO CEO & Investor Conference on February 10, 2009 2Health News:Flavor and Function Are a Hot Match in 2009... Located In a Cool Place 2Health News:ALSIUS CORPORATION PREPARED TO INVALIDATE ZOLL TEMPERATURE MANAGEMENT PATENTS 2
Thermal Transfer Wristbands
Patient-ID™
...I-MATCH III is a label-based patient ID system whi...ification System, an admitting band and up to six ...e only ID band worn by hospital patients. It integ...or blood banks into a multipurpose ID band that co...
Zebra H 2824-Z Healthcare Starter Kit
Medicine Products: